MVIC and Upperton Partner on End-to-End Inhalation Drug Development

COMPANY PROFILE
  • MVIC and Upperton Pharma Solutions have announced a strategic collaboration to provide pharmaceutical and biotechnology companies with an integrated pathway from early drug discovery and formulation development through clinical trial manufacturing.
  • The collaboration combines MVIC’s inhalation and nasal drug development expertise with Upperton’s formulation, spray drying, sterile manufacturing, scale-up, and GMP clinical manufacturing capabilities.

Medicon Valley Inhalation Consortium (MVIC) and Upperton Pharma Solutions have announced a strategic collaboration to provide pharmaceutical and biotechnology companies with an end-to-end drug development and manufacturing service. The collaboration will cover early discovery, formulation development, preclinical support, and clinical trial manufacturing, with the aim of reducing development complexity and accelerating project timelines.

The partnership combines MVIC’s expertise in inhalation and nasal drug development with Upperton’s capabilities in formulation, spray drying, sterile manufacturing, process scale-up, and GMP production of clinical trial materials. The organizations will offer coordinated project management, scientific oversight, and development expertise across the development process, particularly for inhaled, nasal, and other complex drug products requiring specialized formulation and manufacturing support.

MVIC will contribute formulation design, device selection and optimization, preclinical testing, toxicology strategy, regulatory support, and project leadership. Upperton will provide formulation optimization, spray drying, sterile development and manufacturing, process scale-up, GMP clinical manufacturing, packaging and labeling, quality systems support, and distribution for clinical studies.

“Our ambition is to simplify drug development for our customers by offering a seamless route from discovery and early development through clinical manufacturing. Combining the organizations’ scientific, project management, formulation, and manufacturing capabilities would provide a coordinated development pathway.”

Mats Håkansson, CEO of MVIC

Nikki Whitfield, CEO of Upperton Pharma Solutions, said the collaboration would help pharmaceutical innovators progress from initial concepts to clinical evaluation by combining scientific expertise with manufacturing capabilities. The companies also aim to improve knowledge transfer, reduce development risk, and support a smoother transition into clinical manufacturing by working together from the earliest stages of development.

EXCLUSIVE DOWNLOAD

Download the full CDMO Live Report for 112 pages of insights and best practices in external manufacturing.